Clinical experience with monoclonal antibodies to epidermal growth factor receptor.
Recent knowledge about the intermediate steps and final consequences of ligand-dependent epidermal growth factor receptor (EGFR) activation has clearly supported the notion that EGFR plays a fundamental role in regulating the proliferation and survival of malignant neoplasms. Among the rationally designed target-based therapeutics that are being assessed, those targeting EGFR appear to be some of the most clinically relevant. The strategy of using monoclonal antibodies (mAbs) to block ligand binding to the extracellular domain of the EGFR has led to the development of therapeutics that robustly arrest malignant cell proliferation and, in some cases, induce profound tumor regression. The chimeric mAb against EGFR, cetuximab, has already been approved by regulatory agencies worldwide to treat patients with advanced colorectal cancer. Other mAbs against EGFR, particularly panitumumab (ABX-EGF), h-R3, and EMD72000, are in advanced stages of clinical development.
Calvo
Emiliano
E
Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, 7979 Wurzbach Road, 4th Floor, Zeller Building, San Antonio, TX 78229, USA.
Rowinsky
Eric K
EK
D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D017209:Apoptosis / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D000068818:Cetuximab; D002986:Clinical Trials as Topic; D066246:ErbB Receptors / Q000276:immunology*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D000077544:Panitumumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000077544:Panitumumab; D066246:ErbB Receptors; D000068818:Cetuximab
Cancer Res. 1999 Oct 1;59(19):4804-7
10519388
Semin Oncol. 2003 Feb;30(1 Suppl 1):3-11
12644979
Hematol Oncol Clin North Am. 2002 Oct;16(5):1041-63
12512382
Oncogene. 2000 Dec 27;19(56):6550-65
11426640
Cancer Res. 1999 Mar 15;59(6):1236-43
10096554
Cancer Res. 2002 Jun 15;62(12):3335-9
12067969
J Clin Oncol. 2004 Aug 1;22(15):3003-15
15210739
Crit Rev Oncol Hematol. 2001 Apr;38(1):17-23
11255078
Clin Cancer Res. 2003 Apr;9(4):1274-83
12684395
Proc Natl Acad Sci U S A. 1986 Jun;83(11):3825-9
2424012
Cancer Res. 1993 Oct 1;53(19):4637-42
8402640
Br J Cancer. 2004 Aug 2;91(3):418-24
15238978
Cancer Chemother Pharmacol. 2001 Jun;47(6):519-24
11459205
Clin Cancer Res. 2001 Dec;7(12):4230-8
11751524
Blood. 1997 Nov 1;90(9):3322-31
9345014
Semin Oncol. 2002 Feb;29(1 Suppl 4):47-50
11894013
J Clin Oncol. 2004 May 1;22(9):1646-54
15117987
Semin Oncol. 2002 Oct;29(5 Suppl 14):3-9
12422308
J Clin Oncol. 2002 May 15;20(10):2495-9
12011127
Annu Rev Med. 2004;55:433-57
14746530
J Clin Oncol. 2003 Jul 15;21(14):2787-99
12860957
Cancer Immunol Immunother. 1998 May;46(3):167-73
9625540
Clin Cancer Res. 2002 Nov;8(11):3496-502
12429640
Nat Med. 2000 Apr;6(4):443-6
10742152
Clin Cancer Res. 1995 Nov;1(11):1311-8
9815926
J Biol Chem. 1994 Nov 4;269(44):27595-602
7961676
Semin Oncol. 2003 Jun;30(3 Suppl 7):3-14
12840796
Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):984-90
14967460
Cancer Res. 2004 Aug 1;64(15):5355-62
15289342
N Engl J Med. 2004 Jul 22;351(4):337-45
15269313
Oncologist. 2002;7 Suppl 4:2-8
12202782
Nucl Med Biol. 1999 Apr;26(3):275-9
10363798
J Clin Oncol. 2004 Jan 1;22(1):175-84
14701780
J Clin Oncol. 2002 Sep 15;20(18 Suppl):1S-13S
12235219
Oncology (Williston Park). 2003 Nov;17(11 Suppl 12):11-6
14682118
J Natl Cancer Inst. 1993 Aug 18;85(16):1327-33
8340945
Cancer Res. 2001 Dec 15;61(24):8887-95
11751413
Cancer Treat Rev. 2004 May;30(3):255-68
15059649
Eur J Cancer. 2001 Sep;37 Suppl 4:S16-22
11597400
J Clin Oncol. 2004 Apr 1;22(7):1177-9
14993229
J Clin Oncol. 2004 Apr 1;22(7):1201-8
14993230
Oncologist. 2004;9(1):58-67
14755015